CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com

Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’
  • Thu, 22-Dec-2022
  • Posted by: Biocon Biologics
No Comments

Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited
  • Mon, 05-Dec-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business
  • Tue, 29-Nov-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%
  • Tue, 15-Nov-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Features in the Prestigious ASIA IP ELITE List for 2022
  • Fri, 11-Nov-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Ranks at No. 8 in ‘Global Top Employers’ List by the U.S. Science Magazine  
  • Fri, 04-Nov-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Consolidated Statement on USFDA Inspections
  • Wed, 31-Aug-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Statement on Parts of the Charge Sheet Leaked to a Media Outlet
  • Thu, 25-Aug-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility
  • Fri, 05-Aug-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%
  • Wed, 27-Jul-2022
  • Posted by: Biocon Biologics
No Comments
Report adverse event/ side effects and/or product complaints for Biocon Biologics products.

* Safe Harbour | Privacy Policy | Terms of Use © 2022, Biocon Biologics Limited (a Subsidiary of Biocon Limited). All Rights Reserved
Share